CN1698812A - Pharmaceutical composition for treating hepatitis B - Google Patents
Pharmaceutical composition for treating hepatitis B Download PDFInfo
- Publication number
- CN1698812A CN1698812A CN 200510074873 CN200510074873A CN1698812A CN 1698812 A CN1698812 A CN 1698812A CN 200510074873 CN200510074873 CN 200510074873 CN 200510074873 A CN200510074873 A CN 200510074873A CN 1698812 A CN1698812 A CN 1698812A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- radix
- weight
- pharmaceutical composition
- portions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating hepatitis B wherein the composition comprises astragalus root, schisandra fruit, giant knotweed rhizome, oldenlandia, pseudo-ginseng, gen-seng, Bupleurum root, baikal skullcap root, root of red rooted saliva, oriental wormwood and blattbulume.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, particularly relate to a kind of pharmaceutical composition for the treatment of hepatitis B.
Background technology
Hepatitis B (hereinafter to be referred as hepatitis B) is a kind of infectious disease that infects due to the hepatitis B virus, because of its etiology unknown, clinical symptoms or gently or heavily performance differ, and do not have ideal Therapeutic Method again.The whole world has 2.15 hundred million hepatitis b surface antigen positive persons approximately at present, and wherein the Asia-pacific region accounts for 1.68 hundred million, is about 78%.The hepatitis b surface antigen positive person of China then is about 1.2 hundred million.Hepatitis B has become worldwide distribution or popular infectious disease.Because the western medicine effect is not good enough, so the Chinese medicine hepatitis B becomes one of focus of hepatopathy research.Though up to the present, Chinese medicine effect aspect treatment hepatitis B virus index is also not ideal, but with western modern medicine method (as the HBsAg negative conversion rate of interferon therapy about 10%-30%) relatively, because the Chinese medicine therapy is close to the positive rate of rotation and the jamming rate of indexs such as HBsAg, and can improve symptom and sign effectively, and few side effects, medical expense is lower, easy to use, so the Chinese medicine therapy remains one of main method of present treatment hepatitis B patient and symptomless virus carrier.The key of treatment hepatitis B is to improve the immunity of body self at present, strengthens the ability of anti-hepatitis virus, to reach the purpose of final kill virus.Add eating and drinking without temperance again, excessive drinking, inducement such as it is excessive to work causes the heresy of epidemic disease poison, goes into blood system, goes into internal organs, syndromes such as stagnation of liver-QI with deficiency of the spleen occur as dampness-heat in the liver and gallbladder.Pharmaceutical composition of the present invention adopts QI invigorating to set upright, heat-clearing and toxic substances removing, and the promoting flow of QI and blood blood stasis dispelling is main, strengthening vital QI to eliminate pathogenic factors makes liver function recovery, removes hepatitis B virus.
Summary of the invention
The object of the invention is to provide a kind of has remarkable result to the treatment hepatitis B, and can remove the pharmaceutical composition of hepatitis B virus.
The present invention is achieved through the following technical solutions:
Radix Astragali 50-150 weight portion Fructus Schisandrae Chinensis 15-45 weight portion Rhizoma Polygoni Cuspidati 25-75 weight portion
Herba Hedyotidis Diffusae 50-150 weight portion Radix Notoginseng 10-30 weight portion Radix Ginseng 20-60 weight portion
Radix Bupleuri 10-30 weight portion Radix Scutellariae 10-30 weight portion Radix Salviae Miltiorrhizae 15-45 weight portion
Artemisia anethoicles Mattf 15-45 weight portion Cacumen Securinegae Suffruticosae 25-75 weight portion
The optimum ratio of pharmaceutical composition of the present invention is:
The Radix Astragali 100 weight portion Fructus Schisandrae Chinensis 30 weight portion Rhizoma Polygoni Cuspidati 50 weight portions
Herba Hedyotidis Diffusae 100 weight portion Radix Notoginsengs 20 weight portion Radix Ginsengs 40 weight portions
Radix Bupleuri 20 weight portion Radix Scutellariaes 20 weight portion Radix Salviae Miltiorrhizaes 30 weight portions
Artemisia anethoicles Mattf 30 weight portion Cacumen Securinegae Suffruticosaes 50 weight portions
The conventional adjuvant that pharmaceutical composition of the present invention adds is pharmaceutically made clinical acceptable forms, as in tablet, pill, oral liquid, capsule or the granule any.
Pharmaceutical composition of the present invention can make the very fast recovery of liver function normal, and can improve immune function of human body, bring out endogenous interferon and alleviate the downright bad phenomenon generation of hepatocellular degeneration, promote liver cell regeneration, promote albumin synthetic, suppress hepatic fibrosis, suppressing globulin raises, impel hepatitis b virus marker to turn out cloudy, make clinical symptom remission, its satisfactory effect.
Following experimental example is used to further specify the present invention:
The present invention uses the present invention's " post-equalization hall Yiganling " treatment hepatitis B 568 examples from June, 1994～2005 year May, has obtained satisfactory effect clinically, now reports as follows:
1, physical data
Among the 568 routine patients, male's 320 examples wherein, women's 248 examples: age 11-62 year, the course of disease 6 months～19 years, average 6.1 years.Chronic persistent hepatitis 24 examples wherein, chronic active hepatitis 328 examples.Looked into liver function five indices and B ultrasonic during the treatment in every month 1 time.
2, Therapeutic Method
The present invention's's " post-equalization hall Yiganling " medicine is formed: Radix Astragali 100g, Fructus Schisandrae Chinensis 30g, Rhizoma Polygoni Cuspidati 50g, Herba Hedyotidis Diffusae 100g, Radix Notoginseng 20g, Radix Ginseng 40g, Radix Bupleuri 20g, Radix Scutellariae 20g, Radix Salviae Miltiorrhizae 30g, Artemisia anethoicles Mattf 30g, Cacumen Securinegae Suffruticosae 50g.
Preparation technology: technology grinds to the powder altogether routinely, sieves, sterilization, makes honeyed pill.
Specification: every bag of 300g.
Usage: each 10g, use warm water delivery service after meal every day 3 times, child's decrement, 3 months is a course of treatment.
Observe 2～3 courses of treatment, other Chinese and western drugs of stopping using during the treatment changes clothes medicine of the present invention, and 1 state of an illness of 1 month record during the treatment was carried out 1 experimental check in 3 months, and treatment is carried out efficacy evaluation after finishing.
3, criterion of therapeutical effect
Cure: cardinal symptom disappears, and liver function, serum glutamic pyruvic transminase are normal, and the liver spleen recovers normal size, does not have to press and kowtows pain, and various viral indexs are cloudy changes.Follow up a case by regular visits to 1 year no abnormal.
Produce effects: cardinal symptom disappears, and hepatosplenomegaly obviously bounces back, and does not have to press and kowtows pain, and liver function is basic near normal, and HBsAg is weak positive, and HBeAg turns out cloudy.
Take a turn for the better: cardinal symptom is improved or most of the disappearance, and the little constant or retraction to some extent of hepatosplenomegaly presses that to kowtow alleviation of pain light, and liver function and every index descend 50% before the treatment, HBsAg, HBeAg, the sun of turning out cloudy or change among the anti-HBe.
Invalid: symptom and every inspection there is no improvement.
4, therapeutic outcome
Observation of curative effect: among the 568 routine patients, cure 425 examples, account for 74.8%, produce effects 110 examples account for 19.4%, and 21 examples that take a turn for the better account for 3.7%, and invalid 12 examples account for 2.1%, total effective rate 97.9%.
5, model case
Lee * *, man, 45 years old, workman, nineteen ninety-five first visit on July 14.Spiritlessness and weakness appears after the cause fatigue in 2 years, inappetence, dull pain in liver, the rest first quarter moon state of an illness is not felt any better, through chemical examination liver function (unusually) and two double (HBsAg, HbcAb are all positive), examine and be hepatitis B, 20 days symptoms of hospitalization take a turn for the better (but HBsAg, HbcAb are still positive) and leave hospital.Before increase the weight of to go to a doctor because of the back state of an illness of catching a cold over nearly 1 month.Examine and see: spiritlessness and weakness, lack of appetite is indigestion and loss of appetite, the abdominal distention feeling of fullness, dull pain in liver, xerostomia are slightly bitter, oliguria with yellow urine, it is not well to defecate, dizzy dreaminess, there is indentation on the light red tongue limit, and point has petechia, the little Huang of thick and greasy fur, stringy and rolling pulse.Body is looked into: hepatic region tenderness, liver be the 2.5cm place under rib, and matter is soft, and the edge is still sharp keen, and spleen does not touch.Liver function test: ALT1621nmol/ (L.S) TBIL27umol/L, TTT13u, ZnTT18u.Hepatitis B mark HbsAg, HbeAg, HbcAb are all positive.B ultrasonic shows hepatomegaly 3cm, and inner luminous point is thick close even, and Western medicine diagnose is a chronic active hepatitis B.Chinese medical discrimination is a stagnation of liver-QI with deficiency of the spleen, the damp and hot folder stasis of blood.Throw self-control compound recipe hall Yiganling prescription, after 2 months, subjective symptoms disappears, liver retracts to 1.4cm under the rib, and liver function recovery is normal, and HbsAg (-), HbeAg (+), HbcAg (+) continue and obey 3 courses of treatment, liver bounces back to normally, and the hepatitis B mark is all negative, follows up a case by regular visits to end recurrence so far.
Following embodiment is used to further specify the present invention:
Embodiment 1
Radix Astragali 100g Fructus Schisandrae Chinensis 30g Rhizoma Polygoni Cuspidati 50g Herba Hedyotidis Diffusae 100g
Radix Notoginseng 20g Radix Ginseng 40g Radix Bupleuri 20g Radix Scutellariae 20g
Radix Salviae Miltiorrhizae 30g Artemisia anethoicles Mattf 30g Cacumen Securinegae Suffruticosae 50g
Said medicine technology routinely grinds to the powder altogether, sieves, sterilization, makes honeyed pill.Every bag of 300g.Each 10g uses warm water delivery service every day 3 times after meal, child's decrement, and 3 months is a course of treatment.
Embodiment 2
Radix Astragali 70g Fructus Schisandrae Chinensis 40g Rhizoma Polygoni Cuspidati 35g Herba Hedyotidis Diffusae 130g
Radix Notoginseng 15g Radix Ginseng 50g Radix Bupleuri 15g Radix Scutellariae 25g
Radix Salviae Miltiorrhizae 20g Artemisia anethoicles Mattf 40g Cacumen Securinegae Suffruticosae 35g
Said medicine technology is routinely made capsule.
Embodiment 3
Radix Astragali 130g Fructus Schisandrae Chinensis 20g Rhizoma Polygoni Cuspidati 65g Herba Hedyotidis Diffusae 70g
Radix Notoginseng 25g Radix Ginseng 30g Radix Bupleuri 25g Radix Scutellariae 15g
Radix Salviae Miltiorrhizae 40g Artemisia anethoicles Mattf 20g Cacumen Securinegae Suffruticosae 65g
Said medicine technology is routinely made tablet.
Claims (7)
1, a kind of pharmaceutical composition for the treatment of hepatitis B is characterized in that said composition is to be made by following crude drug:
Radix Astragali 50-150 weight portion Fructus Schisandrae Chinensis 15-45 weight portion Rhizoma Polygoni Cuspidati 25-75 weight portion
Herba Hedyotidis Diffusae 50-150 weight portion Radix Notoginseng 10-30 weight portion Radix Ginseng 20-60 weight portion
Radix Bupleuri 10-30 weight portion Radix Scutellariae 10-30 weight portion Radix Salviae Miltiorrhizae 15-45 weight portion
Artemisia anethoicles Mattf 15-45 weight portion Cacumen Securinegae Suffruticosae 25-75 weight portion.
2, pharmaceutical composition according to claim 1 is characterized in that said composition is to be made by following crude drug:
The Radix Astragali 100 weight portion Fructus Schisandrae Chinensis 30 weight portion Rhizoma Polygoni Cuspidati 50 weight portions
Herba Hedyotidis Diffusae 100 weight portion Radix Notoginsengs 20 weight portion Radix Ginsengs 40 weight portions
Radix Bupleuri 20 weight portion Radix Scutellariaes 20 weight portion Radix Salviae Miltiorrhizaes 30 weight portions
Artemisia anethoicles Mattf 30 weight portion Cacumen Securinegae Suffruticosaes 50 weight portions.
3, pharmaceutical composition according to claim 1 is characterized in that said composition is to be made by following crude drug:
The Radix Astragali 70 weight portion Fructus Schisandrae Chinensis 40 weight portion Rhizoma Polygoni Cuspidati 35 weight portions
Herba Hedyotidis Diffusae 130 weight portion Radix Notoginsengs 15 weight portion Radix Ginsengs 50 weight portions
Radix Bupleuri 15 weight portion Radix Scutellariaes 25 weight portion Radix Salviae Miltiorrhizaes 20 weight portions
Artemisia anethoicles Mattf 40 weight portion Cacumen Securinegae Suffruticosaes 35 weight portions.
4, pharmaceutical composition according to claim 1 is characterized in that said composition is to be made by following crude drug:
The Radix Astragali 130 weight portion Fructus Schisandrae Chinensis 20 weight portion Rhizoma Polygoni Cuspidati 65 weight portions
Herba Hedyotidis Diffusae 70 weight portion Radix Notoginsengs 25 weight portion Radix Ginsengs 30 weight portions
Radix Bupleuri 25 weight portion Radix Scutellariaes 15 weight portion Radix Salviae Miltiorrhizaes 40 weight portions
Artemisia anethoicles Mattf 20 weight portion Cacumen Securinegae Suffruticosaes 65 weight portions.
5,, it is characterized in that the conventional adjuvant that said composition adds pharmaceutically makes the dosage form of clinical acceptance according to claim 1,2,3 or 4 described pharmaceutical compositions.
6, pharmaceutical composition according to claim 5 is characterized in that described dosage form is tablet, pill, oral liquid, capsule or granule.
7,, it is characterized in that the application of said composition in preparation treatment hepatitis B medicament according to claim 1,2,3 or 4 described pharmaceutical compositions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510074873 CN1698812A (en) | 2005-06-07 | 2005-06-07 | Pharmaceutical composition for treating hepatitis B |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510074873 CN1698812A (en) | 2005-06-07 | 2005-06-07 | Pharmaceutical composition for treating hepatitis B |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1698812A true CN1698812A (en) | 2005-11-23 |
Family
ID=35475166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510074873 Pending CN1698812A (en) | 2005-06-07 | 2005-06-07 | Pharmaceutical composition for treating hepatitis B |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1698812A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1903273B (en) * | 2006-08-07 | 2010-05-12 | 广西壮族自治区中医药研究所 | Medicine for treating hepatitis and its preparation method |
| CN101912524A (en) * | 2010-08-15 | 2010-12-15 | 卢静 | Schisandra liver-benefiting capsules |
| CN101485753B (en) * | 2008-12-31 | 2012-01-11 | 天科仁祥技术（北京）有限责任公司 | Chinese medicine for treating hepatitis B and preparation method thereof |
| CN101375951B (en) * | 2007-08-29 | 2012-03-07 | 北京星昊嘉宇医药科技有限公司 | Medicine composition for treating hepatitis B |
| CN102764337A (en) * | 2012-08-20 | 2012-11-07 | 马驰 | Traditional Chinese medicine composition for curing hepatitis B |
| CN104644867A (en) * | 2015-03-17 | 2015-05-27 | 邵国辉 | Combination medicine for improving anti-HBV curative effect of interferon and preparation method of combination medicine |
| CN111228388A (en) * | 2020-03-25 | 2020-06-05 | 王朝开 | A pharmaceutical composition for treating hepatopathy, and its application method |
-
2005
- 2005-06-07 CN CN 200510074873 patent/CN1698812A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1903273B (en) * | 2006-08-07 | 2010-05-12 | 广西壮族自治区中医药研究所 | Medicine for treating hepatitis and its preparation method |
| CN101375951B (en) * | 2007-08-29 | 2012-03-07 | 北京星昊嘉宇医药科技有限公司 | Medicine composition for treating hepatitis B |
| CN101485753B (en) * | 2008-12-31 | 2012-01-11 | 天科仁祥技术（北京）有限责任公司 | Chinese medicine for treating hepatitis B and preparation method thereof |
| CN101912524A (en) * | 2010-08-15 | 2010-12-15 | 卢静 | Schisandra liver-benefiting capsules |
| CN102764337A (en) * | 2012-08-20 | 2012-11-07 | 马驰 | Traditional Chinese medicine composition for curing hepatitis B |
| CN102764337B (en) * | 2012-08-20 | 2014-04-09 | 马驰 | Traditional Chinese medicine composition for curing hepatitis B |
| CN104644867A (en) * | 2015-03-17 | 2015-05-27 | 邵国辉 | Combination medicine for improving anti-HBV curative effect of interferon and preparation method of combination medicine |
| CN111228388A (en) * | 2020-03-25 | 2020-06-05 | 王朝开 | A pharmaceutical composition for treating hepatopathy, and its application method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1698812A (en) | Pharmaceutical composition for treating hepatitis B | |
| CN1927330A (en) | Chinese medicine composition for treating gout and preparing method thereof | |
| CN1692939A (en) | Traditional Chinese medicine pill for treating hepatitis B, and its prepn. method | |
| CN1476849A (en) | Medicine composition for promoting blood circulation and removing stasis | |
| CN1720965A (en) | Chinese medicinal composition for treating acute icterohepatitis | |
| CN1243743A (en) | Medicine for treating chronic hepatism and its preparing process | |
| CN1223374C (en) | Chinese medicinal composition for treating hepatitis B | |
| CN1052889C (en) | Chinese proprietary for curing hepatitis | |
| CN101045152A (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease concomitant inflammatory swelling | |
| CN1106690A (en) | Medicine of curing hepatitis | |
| CN1493315A (en) | Medicine for treating chronic hepatitis B | |
| CN1939498A (en) | Chinese-medicinal preparation for treating psoriasis | |
| CN1112194C (en) | Compound yexiazhu medicine and preparing process thereof | |
| CN1319587C (en) | Medicine powder for liver and spleen diseases | |
| CN1294980C (en) | Medicine for treating liver disease | |
| CN1302799C (en) | Oral Chinese medicinal composition for treating virus myocarditis | |
| CN1169570C (en) | Medicine for treating acute and chronic hepatitis B | |
| CN104547070A (en) | Medical composition resistant to hepatitis b viruses as well as preparation method and application of medical composition | |
| CN1965968A (en) | Orally administered medicinal powder for treating gastric diseases | |
| CN1116890C (en) | Medicine for treating hepatitis B | |
| CN1903347A (en) | Medicine composition for treating alimentary canal diseases, prepn. method and application thereof | |
| CN103505500B (en) | A kind of Chinese medicine composition for the treatment of hepatitis B and preparation method thereof | |
| CN1159057C (en) | Medicine for treating hepatitis, and preparing process thereof | |
| CN1146362A (en) | Capsule for anti hepatitis B | |
| CN101057912A (en) | Medicine for treating hepatitis and cirrhosis ascites and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |